Literature DB >> 11891202

Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation.

Kathleen C Flanders1, Catherine D Sullivan, Makiko Fujii, Anastasia Sowers, Mario A Anzano, Alidad Arabshahi, Christopher Major, Chuxia Deng, Angelo Russo, James B Mitchell, Anita B Roberts.   

Abstract

Transforming growth factor-beta (TGF-beta) plays a central role in the pathogenesis of inflammatory and fibrotic diseases, including radiation-induced fibrosis. We previously reported that mice null for Smad3, a key downstream mediator of TGF-beta, show accelerated healing of cutaneous incisional wounds with reduced inflammation and accumulation of matrix. To determine if loss of Smad3 decreases radiation-induced injury, skin of Smad3+/+ [wild-type (WT)] and -/- [knockout (KO)] mice was exposed to a single dose of 30 to 50 Gy of gamma-irradiation. Six weeks later, skin from KO mice showed significantly less epidermal acanthosis and dermal influx of mast cells, macrophages, and neutrophils than skin from WT littermates. Skin from irradiated KO mice exhibited less immunoreactive TGF-beta and fewer myofibroblasts, suggesting that these mice will have a significantly reduced fibrotic response. Although irradiation induced no change in the immunohistochemical expression of the TGF-beta type I receptor, the epidermal expression of the type II receptor was lost after irradiation whereas its dermal expression remained high. Primary keratinocytes and dermal fibroblasts prepared from WT and KO mice showed similar survival when irradiated, as did mice exposed to whole-body irradiation. These results suggest that inhibition of Smad3 might decrease tissue damage and reduce fibrosis after exposure to ionizing irradiation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11891202      PMCID: PMC1867194          DOI: 10.1016/S0002-9440(10)64926-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  63 in total

1.  Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo.

Authors:  W R Waldrip; E K Bikoff; P A Hoodless; J L Wrana; E J Robertson
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

Review 2.  SMADs: mediators and regulators of TGF-beta signaling.

Authors:  M Kretzschmar; J Massagué
Journal:  Curr Opin Genet Dev       Date:  1998-02       Impact factor: 5.578

3.  Protection from radiation-induced alopecia with topical application of nitroxides: fractionated studies.

Authors:  D Cuscela; D Coffin; G P Lupton; J A Cook; M C Krishna; R F Bonner; J B Mitchell
Journal:  Cancer J Sci Am       Date:  1996 Sep-Oct

4.  Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells.

Authors:  T A McCaffrey; B Du; S Consigli; P Szabo; P J Bray; L Hartner; B B Weksler; T A Sanborn; G Bergman; H L Bush
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

5.  Differential regulation of keratinocyte growth factor and hepatocyte growth factor/scatter factor by different cytokines in human corneal and limbal fibroblasts.

Authors:  D Q Li; S C Tseng
Journal:  J Cell Physiol       Date:  1997-09       Impact factor: 6.384

6.  Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2.

Authors:  M Weinstein; X Yang; C Li; X Xu; J Gotay; C X Deng
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

7.  Smad2 role in mesoderm formation, left-right patterning and craniofacial development.

Authors:  M Nomura; E Li
Journal:  Nature       Date:  1998-06-25       Impact factor: 49.962

8.  Smad3 mutant mice develop metastatic colorectal cancer.

Authors:  Y Zhu; J A Richardson; L F Parada; J M Graff
Journal:  Cell       Date:  1998-09-18       Impact factor: 41.582

9.  Human Smad3 and Smad4 are sequence-specific transcription activators.

Authors:  L Zawel; J L Dai; P Buckhaults; S Zhou; K W Kinzler; B Vogelstein; S E Kern
Journal:  Mol Cell       Date:  1998-03       Impact factor: 17.970

10.  The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1.

Authors:  G Serini; M L Bochaton-Piallat; P Ropraz; A Geinoz; L Borsi; L Zardi; G Gabbiani
Journal:  J Cell Biol       Date:  1998-08-10       Impact factor: 10.539

View more
  94 in total

1.  Interference with transforming growth factor-beta/ Smad3 signaling results in accelerated healing of wounds in previously irradiated skin.

Authors:  Kathleen C Flanders; Christopher D Major; Alidad Arabshahi; Ekinadese E Aburime; Miya H Okada; Makiko Fujii; Timothy D Blalock; Gregory S Schultz; Anastasia Sowers; Mario A Anzano; James B Mitchell; Angelo Russo; Anita B Roberts
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

Review 2.  Fibrotic disease and the T(H)1/T(H)2 paradigm.

Authors:  Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

3.  RLP, a novel Ras-like protein, is an immediate-early transforming growth factor-beta (TGF-beta) target gene that negatively regulates transcriptional activity induced by TGF-beta.

Authors:  Ester Piek; Maarten Van Dinther; W Tony Parks; John M Sallee; Erwin P Böttinger; Anita B Roberts; Peter Ten Dijke
Journal:  Biochem J       Date:  2004-10-01       Impact factor: 3.857

4.  Eosinophilic Esophagitis-Associated Chemical and Mechanical Microenvironment Shapes Esophageal Fibroblast Behavior.

Authors:  Amanda B Muir; Kara Dods; Steven J Henry; Alain J Benitez; Dale Lee; Kelly A Whelan; Maureen DeMarshall; Daniel A Hammer; Gary Falk; Rebecca G Wells; Jonathan Spergel; Hiroshi Nakagawa; Mei-Lun Wang
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-08       Impact factor: 2.839

5.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

6.  Efficacy of ALK5 inhibition in myelofibrosis.

Authors:  Lanzhu Yue; Matthias Bartenstein; Wanke Zhao; Wanting Tina Ho; Ying Han; Cem Murdun; Adam W Mailloux; Ling Zhang; Xuefeng Wang; Anjali Budhathoki; Kith Pradhan; Franck Rapaport; Huaquan Wang; Zonghong Shao; Xiubao Ren; Ulrich Steidl; Ross L Levine; Zhizhuang Joe Zhao; Amit Verma; Pearlie K Epling-Burnette
Journal:  JCI Insight       Date:  2017-04-06

Review 7.  Transgenic modeling of transforming growth factor-beta(1): role of apoptosis in fibrosis and alveolar remodeling.

Authors:  Chun Geun Lee; Hye-Ryun Kang; Robert J Homer; Geoffrey Chupp; Jack A Elias
Journal:  Proc Am Thorac Soc       Date:  2006-07

Review 8.  Improving Wound Healing with Topical Gene Therapy.

Authors:  John Layliev; Stelios Wilson; Stephen M Warren; Pierre B Saadeh
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-10       Impact factor: 4.730

9.  Development of antisense oligonucleotide (ASO) technology against Tgf-β signaling to prevent scarring during flexor tendon repair.

Authors:  Alayna E Loiselle; Kiminori Yukata; Michael B Geary; Sirish Kondabolu; Shanshan Shi; Jennifer H Jonason; Hani A Awad; Regis J O'Keefe
Journal:  J Orthop Res       Date:  2015-06       Impact factor: 3.494

10.  SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease.

Authors:  Sharyle A Fowler; Ashwin N Ananthakrishnan; Agnes Gardet; Christine R Stevens; Joshua R Korzenik; Bruce E Sands; Mark J Daly; Ramnik J Xavier; Vijay Yajnik
Journal:  J Crohns Colitis       Date:  2014-01-24       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.